drugset / Trial / NCT02254109

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers

NCT02254109

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate safety, tolerability, and pharmacokinetics of BEA 2180 BR in Japanese healthy volunteers

Timeline

Start
2008-04
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BEA 2180 BR Unknown 50 ug
Subject BEA 2180 BR Unknown 100 ug
Subject BEA 2180 BR Unknown 200 ug

Indications

No indication recorded.